29/12/2021 - Covid-19
Patients with type-2 diabetes affected by COVID-19 are four to five times more likely to die or suffer serious complications from the disease if their blood sugar levels are much higher or much lower than usual This has been revealed in a study led by the Endocrinology and Nutrition Service at Hospital del Mar and published in the journal Diabetes Care The ratio of glucose levels on arrival in the emergency room to the patient's usual levels has a high predictive value, more so than either of the two data separately. These levels can be determined easily through a blood test
27/12/2021 - General information
AELIS FARMA, a biotechnology company specializing in the treatment of brain disorders, announces today that AEF0217 has been administered to the first cohort of healthy volunteers, as part of a phase 1 clinical study to assess the safety, tolerability and the pharmacokinetic characteristics of its second drug candidate. The administration of AEF0217, using a dose in the expected therapeutic range, has good tolerability and demonstrates encouraging safety and plasma exposure characteristics for further clinical development. This phase 1 program is part of the European H2020 ICOD project (Improving COgnition in Down syndrome) which is led in collaboration with Hospital del Mar Medical Research Institute (IMIM) in Barcelona, and Prof. Raphael de la Torre Fornell, coordinator of the project and the principal investigator of the study. In February 2021, the ICOD project received funding of €6m from the European Commission to finance the clinical development of AEF0217 for the treatment of cognitive deficits linked to Down syndrome.
22/12/2021 - Institutional news
From 2022, the World Anti-Doping Agency's (WADA) list of prohibited substances and methods in sport is to include important changes regarding the use of glucocorticoids in sport. From this point on, all injectable methods will be prohibited during competitions, in addition to oral and rectal administration. Other ways of receiving the medication, such as via inhalation, intranasal or dermatological routes, will continue to be permitted if their use is necessary for therapeutic reasons. There will still be no restrictions on the use of glucocorticoids in out-of-competition periods. Criteria have also been defined to improve the safety of glucocorticoid administration for therapeutic reasons. Firstly, the distinction between prohibited and permitted routes of administration has been improved by defining a specific information concentration for each glucocorticoid. Secondly, blanking periods after prohibited treatments have been defined so that those performed in out-of-competition periods close to competitions do not lead to false positive results in samples collected during competitions.
22/12/2021 - Institutional news
The Director of the Addictions Process at INAD and researcher at the Hospital del Mar Medical Research Institute becomes a member of the executive committee of this organization that promotes knowledge and research on dual pathology. The congress of the World Association on Dual Disorders (WADD) approved at its congress, held in Paris between December 7 and 9, the incorporation of Dr. Marta Torrens to its executive committee. Thus, the Director of the Addictions Process of the Institute of Neuropsychiatry and Addictions of the Hospital del Mar (INAD) and coordinator of the Addictions Research Group of the Hospital del Mar Medical Research Institute (IMIM), will participate in the organization's decision-making, such as the organization of congresses, training courses and publications.
20/12/2021 - General information
The urgent need to find treatments for a large number of degenerative diseases has led a group of experts to develop a guide designed to accelerate new drug discoveries for neurological and psychiatric diseases. Project leads are Dr. Silvia Zaragoza Domingo, consultant and founder of Neuropsynchro, Barcelona, serving as coordinator collaborating with Drs. Jordi Alonso and Montserrat Ferrer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM) and CIBERESP, and Dr. Manuel de Gracia, Facultat de Psicologia of Universitat de Girona (UdG). This guide was presented during the 34th Congress of the European Clinical Neurosychopharmacological College (ECNP) in Lisbon on 2-5 October and has been the group's priority project since it was established in 2018.
14/12/2021 - Press release
This new resource, developed by the GPCR Drug Discovery Group at the Hospital del Mar Medical Research Institute, provides a three-dimensional analysis of the movements of COVID-19 proteins. This can help researchers understand how they work and develop new treatments and vaccines The tool, available online to all researchers, offers a large number of simulations of how these proteins work, as well as resources for predicting how their function could change in relation to mutations that may occur in the structure of this coronavirus The scientists behind the initiative used more than 360 gigabits of data to develop it. To date, it is the only database for studying SARS-CoV-2 that combines protein simulations with mutation data
03/12/2021 - Institutional news
The Hospital del Mar Medical Research Institute (IMIM) has signed a five-year contract with the World Anti-Doping Agency (WADA, https://www.wada-ama.org/ ), within the framework of a tender of offers at an international level, worth € 1,880,000, for the preparation of reference materials for its external quality assessment program of laboratories (EQAS) accredited to carry out anti-doping control around the world (WADA's External Quality Assessment Scheme). Dr. Oscar Pozo, group leader of the Applied Metabolomics Research Group of the Neurosciences Research Program at IMIM, will be responsible for the execution of the contract as of January 2022.
02/12/2021 - Press release
A study using mice shows that animals fed a diet rich in beneficial live microorganisms suffer less from the addictive effects of alcohol consumption. The work has been published in the journal Frontiers in Nutrition. It is the first to analyse the possible relationship between intestinal bacteria and the possibility of altering addictive behaviours related to alcohol use. In the study, animals that maintain a healthy microbiota also avoid addiction relapse and have lesser effects from associated disorders such as depression and anxiety.
01/12/2021 - General information
The board of the Spanish Society of Pneumology and Thoracic Surgery has decided that the Hospital del Mar pneumologist and researcher at the Hospital del Mar Medical Research Institute will head up the committee responsible for managing and organising the society's policy documents. The Spanish Society of Pneumology and Thoracic Surgery (SEPAR), has appointed Dr. Esther Barreiro, a consultant in the Pneumology Department at Hospital del Mar and coordinator of the Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer Research Group at the Hospital del Mar Medical Research Institute (IMIM), as coordinator of the SEPAR committee responsible for managing the regulations and recommendations that will be issued by the society. The appointment was made at the first meeting of the new SEPAR governing board.
Més informació "Dr. Esther Barreiro, coordinator of SEPAR regulations and recommendations"
29/11/2021 - Institutional news
The Emeritus Head of the Surgery Department at Hospital del Mar and researcher at the Hospital del Mar Institute of Medical Research became a full member of the RAMC, in a ceremony held on 29 November at the institution's headquarters. Dr. Lluís Grande is now a full member of the Royal Academy of Medicine of Catalonia. The appointment was made on 29 November, in a ceremony held at the institution's headquarters, in which the Emeritus Head of the Surgery Department at Hospital del Mar and researcher at the Hospital del Mar Institute of Medical Research (IMIM), delivered the speech, "Showing the data: a recipe for improving quality in an academic surgery department." The response was given by Dr. Laureà Fernández-Cruz, also a full member of the RAMC.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
